This FAQ discusses the PROTECT series of FDA clinical studies, which includes PROTECT I, the PROTECT II RCT and PROTECT III, is the largest-ever study of hemodynamically supported high-risk PCI patients.
Jena Billig discusses heparin-free purge solution and the features of the second-generation Impella 5.5® with SmartAssist® in this critical care transport webinar.
This article examines current evidence for the use of mechanical circulatory support (MCS) in cardiogenic shock and discusses how the scientific community can advance research in this area.
This paper discusses the latest guidance for identifying patients with cardiogenic shock (CS) who are candidates for mechanical circulatory support (MCS).
In this article the authors describe techniques for Impella heart pump removal with or without pre-closure and discuss how to prevent and manage complications associated with large-bore femoral access.
This article describes how the interventional cardiology team handles high-risk patients in the cath lab, from procedural preparation and planning through procedural monitoring, as well as weaning strategies and access site management.
Alan Gass, M.D., FACC from Westchester Medical Center presents a case of a 48-year-old male without prior medical history who presented to a local hospital with several hours of chest pain.
NPS-1674
This information is intended for use by customers, patients, and healthcare professionals in [region] only. We recognize that the Internet is a global communications medium; however, laws, regulatory requirements, and product information for medical products can vary from country to country. The product information included here may not be appropriate for use outside [region], and the information from other sites you visit may not be appropriate for use in [region].
The Protected PCI community
is now on HeartRecovery.com
Providing education and training to help health care professionals
recover hearts, oxygenate the body and save lives.
